Single Photon Emission Computed Tomography Market By Product Type (Standalone SPECT Systems, CT Systems, Gamma Cameras, Software & Services, Radiopharmaceuticals), By Radiopharmaceutical Type (Technetium-99m-Based Agents, Thallium-201, Iodine-131, Indium-Based Agents, Novel Targeted Tracers), By Technology (Conventional NaI(Tl) Scintillation Detectors, Solid-State (CZT) Detectors, Single-Head Systems, Multi-Head Systems), By Application (Cardiology, Neurology, Oncology, Bone & Musculoskeletal Imaging, Renal, Pulmonary, and Endocrine Studies, Others), By End-User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Research & Academic Institutes, Pharmaceutical & Biotech Companies, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025 – 2035.

---

What trends will shape the Single Photon Emission Computed Tomography Market in the coming years?

The Single Photon Emission Computed Tomography Market accounted for USD 3.92 Billion in 2024 and USD 4.03 Billion in 2025 is expected to reach USD 5.32 Billion by 2035, growing at a CAGR of around 2.82% between 2025 and 2035. The Single Photon Emission Computed Tomography Market has great potential to grow, as the prevalence of cardiovascular and neurological diseases and the need for early and precise diagnosis are on the rise. Implementation of hybrid SPECT/CT systems is improving anatomic and functional imaging and increasing diagnostic accuracy. New developments in solid-state CZT detectors are allowing scans to be quicker, more sensitive, and with a reduced dose of radiation. Increasing adoption of AI and high-quality imaging software to perform quantification and automated analysis is facilitating workflows and enhancing patient outcomes.

New clinical opportunities are emerging because of the increasing oncology and personalized medicine applications. The development of radiopharmaceuticals, such as new targeted tracers, is expanding diagnostic possibilities. There is a growing investment in the healthcare sector and the building of imaging infrastructure in emerging markets. Also, SPECT is becoming more affordable in hospitals and diagnostic centers around the world due to cost-effective refurbished systems and service-based models.

What do industry experts say about the Single Photon Emission Computed Tomography market trends?

“Tomer brings a wealth of experience in the field of medical imaging and a proven track record of driving growth at Spectrum Dynamics for the last nine years while serving as the company's CFO. With a passion for improving patient outcomes, we are confident that Tomer will lead Spectrum Dynamics to newer and greater heights as we build on our legacy of excellence and continue to serve as a global leader in cutting-edge medical imaging technology.”

• Tomer Gabay, CEO of Spectrum Dynamics Medical.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Single Photon Emission Computed Tomography market?

How will rising cardiovascular diseases globally accelerate the adoption of advanced SPECT imaging systems?

The Single Photon Emission Computed Tomography Market is showing tremendous growth owing to the increased incidence of cardiovascular diseases in the world. The World Health Organization estimates that in 2019, 17.9 million people died due to cardiovascular diseases, about 32% of the total number of deaths in the world. This is a very worrying figure that highlights the necessity of sophisticated diagnostic equipment. SPECT imaging with or without computed tomography (CT) can provide improved functional and anatomical imaging and result in the early detection and accurate localization of cardiac abnormalities. These functions play an important role in the treatment of such conditions as coronary artery disease and myocardial infarction.

The rising occurrence of cardiovascular diseases has contributed to the growing need for non-invasive yet precise diagnostic processes, and this has accelerated the use of SPECT/CT systems in medical institutions across the globe. Moreover, radiopharmaceutical development and detector technologies are enhancing the sensitivity and resolution of SPECT imaging and thus becoming the choice of clinicians. Image interpretation and patient outcomes are also improving with the integration of artificial intelligence and SPECT imaging. Raised awareness on the part of healthcare providers and patients on the importance of early diagnosis is also in favor of SPECT uptake. As cardiovascular disease remains a growing burden on the world, advanced SPECT imaging systems are an important element to enhance cardiovascular care and patient prognosis.

Can technological innovations in CZT detectors enhance scan speed and image accuracy significantly?

The Single Photon Emission Computed Tomography Market has been exhibiting vigorous development as a result of the development in detector technologies. CdZnTelluride (CZT) detectors have become a game changer, having a better energy resolution and spatial resolution than the conventional sodium iodide detectors. Systems based on CZT SPECTs also show high-quality images and diagnostic capability, especially in cardiac imaging. These enhancements are explained by the fact that CZT could directly convert gamma rays into electrical signals, without the use of complicated photomultiplier tubes, and allowed a faster image acquisition.

CZT detectors have a compact size and high sensitivity, which makes them more efficient at imaging and able to achieve faster patient throughput in the clinical environment. Also, the detectors allow low doses of radiation to be used without sacrificing the quality of the images, making the patients safer. The technology is also extending further than cardiology into other fields of neurology and oncology, where accurate imaging is essential in the diagnosis. Image reconstruction and interpretation are enhanced further with the integration of CZT systems with high-level software. CZT-based SPECT systems are adopted to help improve workflow and clinical decisions. Overall, innovations in CZT detectors are contributing to the dramatic increase in scan speed, image accuracy, and patient care in the SPECT imaging market.

Does the high cost of SPECT systems limit adoption in small hospitals or clinics?

The SPECT imaging market is characterized by low adoption in small hospitals and clinics because the equipment is very expensive. State-of-the-art SPECT systems, especially hybrid SPECT/CT systems and CZT-based detectors, are very expensive to buy and set up. Besides startup costs, there are also maintenance costs, software upgrades, and radiopharmaceutical supplies, which further add to the financial burden. Smaller healthcare organizations have limited budgets, and hence, it may be hard to justify the cost of investing in costly imaging technologies.

Costly prices may impede or make SPECT systems adoption impossible, limiting access to state-of-the-art diagnostic services in underserved areas. This is a weakness in the early detection of diseases, especially those of the cardiovascular, neurological, and oncological types. Other hospitals are trying to subsidize by means of shared imaging centers or leasing facilities, which is not universal. Financial barriers can be partially overcome with the assistance of reimbursement policies and government assistance, but the challenges are still serious. Irrespective of these limitations, the demand still increases because of the clinical advantages and precision of SPECT imaging. In general, cost is a significant constraint that restricts the adoption of SPECT systems in small-scale healthcare settings.

How can hybrid SPECT/CT systems expand clinical applications across oncology and neurological imaging?

The SPECT imaging market has been developing fast because of the development of hybrid SPECT/CTs. These systems integrate both a functional image derived through the use of SPECT and an anatomic image, which is derived through the use of CT. Hybrid SPECT/CT systems help accurately localize tumors in oncology, which better stage treatment planning and monitor the therapy. In the case of neurological applications, they can be used to perform detailed evaluations of the brain structure and functionality, which is useful in the diagnosis of neurological diseases like Alzheimer's disease, epilepsy, and Parkinson's disease. The SPECT and CT technologies can be integrated to increase the quality of images, shorten scan time, and make the procedures more comfortable for patients.

Hybrid systems have attenuation correction, and this guarantees higher levels of uptake of radiotracers, hence better clinical decisions. Personalized medicine can also be supported through the adoption of these systems that allow treatment strategies to be personalized based on the needs of the individual patient. Practitioners are also investing in hybrid SPECT/CT so that they can improve the quality of diagnosis and efficiency of workflow. The fact that they can provide anatomical and functional data is broadening clinical uses in various specialties. On the whole, the hybrid SPECT/CT technology transforms medical imaging and enhances patient outcomes in oncology and neurology.

Will emerging markets with improving healthcare infrastructure drive new SPECT system installations?

The Single Photon Emission Computed Tomography Market of imaging is booming, particularly in the emerging markets with upgraded healthcare systems. In India, the government has characterized hundreds of billions worth of investment opportunities in hospital and medical infrastructure to increase healthcare accessibility in Tier 2 and Tier 3 cities. Programs such as the Ayushman Bharat project, which is set to create 1.5 lakh wellness centers, are fueling the need to adopt better diagnostic technologies such as SPECT systems. Better health care centers and increased enlightenment on the need to detect diseases at an early stage are influencing the use of modern imaging devices in hospitals and diagnostic centers.

SPECT system manufacturers are working towards these markets more to exploit the growth opportunities. The government support and subsidies, together with the expansion of infrastructure, help in installing and using high-level imaging systems. There is also support for the increase of diagnosis centers and the availability of trained professionals, which adds to their contribution to the expansion of the market. These advancements are allowing the developing economies to acquire technologies that were once exclusive to the developed economies. Higher adoption rates are a result of increasing patient volumes in cardiovascular, neurological, or oncological conditions. Overall, the developing healthcare environment in the emerging markets presents substantial prospects for the development of the SPECT imaging market.

What are the key market segments in the Single Photon Emission Computed Tomography industry?

Based on the product type, the Single Photon Emission Computed Tomography Market is classified into Standalone SPECT Systems, CT Systems, Gamma Cameras, Software & Services, and Radiopharmaceuticals. Individual SPECT systems are popular in hospitals and diagnostic centers to make regular nuclear images. The CT systems with the SPECT offer hybrid imaging solutions that enhance both the anatomical and functional diagnostic accuracy. Gamma cameras are still a vital device to identify gamma radiation emitted by radiotracers in the body.

Software & Services contain modern reconstruction schemes, image processing solutions, and maintenance models, and improve the efficiency of the workflow. Techniques like radiopharmaceuticals, which are technetium-99m and thallium-201, are important in facilitating the accurate imaging of organs and tissues. The increased cardiovascular, neurological, and oncological diseases are increasing the need for these products. The growth of the market is likely to accelerate further during the forecast period due to an increased use of hybrid technologies and AI-enabled software.

Based on the application, the Single Photon Emission Computed Tomography Market is classified into Cardiology, Neurology, Oncology, Bone & Musculoskeletal Imaging, Renal, Pulmonary, and Endocrine Studies, and Others. The largest application segment is cardiology, which is due to the rising number of cardiovascular diseases and the necessity to have accurate myocardial perfusion imaging. Applications in the field of neurology are growing at an alarming rate, and SPECT is being applied in the diagnosis of dementia, Parkinson's disease, and epilepsy.

Oncology uses SPECT to detect, stage, and monitor the progression of tumor treatment and improve its individual treatment planning. The imaging of the bones and musculoskeletal system contributes to the evaluation of fractures, arthritis, and other disorders of the bones. Renal, pulmonary, and endocrine images with the help of SPECT are used to assess the organs' functionality and identify the abnormalities effectively. Additional uses are in imaging of infections, inflammation, and research studies. The increasing use of hybrid SPECT/CT devices and more sophisticated imaging software is expanding the fields of clinical use in several areas of therapy.

Which regions are leading the Single Photon Emission Computed Tomography market, and why?

The North American Single Photon Emission Computed Tomography Market is leading due to the medical care system having an advanced structure, and innovation in imaging technologies is widely used. The US is the largest contributor because of increasing cases of cardiovascular, neurological, and cancerous diseases. The extensive use of SPECT is supported by the availability of high-quality equipment and specialists in healthcare facilities and the presence of well-established hospitals and diagnostic centers. Market growth is further enhanced by high investment in research and development and government activities in nuclear medicine.

Clinical efficiency and accuracy in diagnostic imaging are increasing at a rapid pace with hybrid SPECT/CT systems and the use of AI-based software. The radiopharmaceuticals like technetium-99m and thallium-201 are available to ensure there is no disruption of the imaging services. There are also good reimbursement policies in North America, which motivate hospitals and clinics to purchase modern SPECT systems. Overall, technological innovation and the growing need for early disease detection are making the region remain a leader in the global SPECT market.

The Asia Pacific Single Photon Emission Computed Tomography Market is growing due to the rising levels of investment in healthcare and the development of nuclear imaging systems. Agreements on the use of advanced SPECT and hybrid SPECT/CT systems are being rapidly adopted in countries such as China, India, and Japan. The increasing number of cardiovascular, neurological, and oncological diseases is contributing to the increased demand for early and precise diagnosis.

Market expansion is being helped by government efforts to make healthcare more accessible and subsidize state-of-the-art imaging technologies. This is further increasing the adoption due to the presence of skilled professionals and the increasing number of diagnostic centers. The efficiency of the diagnosis is increasing due to the development of new technologies, such as AI-based imaging software and solid-state CZT detectors. Raising the awareness of preventive healthcare among the population is a positive stimulus to regular imaging tests. In general, the region has good prospects of recording high growth, which is very promising to the global and local manufacturers of SPECT equipment.

What does the competitive landscape of the Single Photon Emission Computed Tomography market look like?

The Single Photon Emission Computed Tomography Market is highly competitive, with the industry giants like Siemens Healthineers, GE HealthCare, Canon Medical Systems, Spectrum Dynamics Medical, and Lantheus Holdings leading in innovation. Corporations are also going extravagant on research and development to enhance imaging resolution, scan speed, and artificial intelligence to diagnose more efficiently. Strategic partnerships, mergers, collaborations, and increasing technological capabilities and access to international markets are the order of the day. As an example, Siemens Healthineers has recently announced that it will join forces with an AI software manufacturer and deploy machine learning algorithms in its SPECT systems to ensure a faster and more precise image processing in its diagnostics.  Niche applications and affordable solutions are being targeted at small hospitals and emerging markets in an effort by emerging players.

The regulatory approvals, strict quality requirements, and reimbursement policies among the countries also influence the market competition. The trend to hybrid SPECT/CT systems is growing, as anatomical and functional imaging is utilized to perform the full diagnostics. Solid-state CZT detectors are also being improved in terms of sensitivity and radiation exposure with the aid of technological progress. Firms are also focusing on the after-sales services, software upgrades, and training as a way of enhancing customer loyalty. In general, innovation, strategic partnerships, and the increase of applications are common characteristics that determine the competitive environment in the SPECT market.

Single Photon Emission Computed Tomography Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Single Photon Emission Computed Tomography industry?

• In

Report Coverage:

By Product Type

• Standalone SPECT Systems
• CT Systems
• Gamma Cameras
• Software & Services
• Radiopharmaceuticals

By Radiopharmaceutical Type

• Technetium-99 m-Based Agents
• Thallium-201
• Iodine-131
• Indium-Based Agents
• Novel Targeted Tracers

By Technology

• Conventional NaI(Tl) Scintillation Detectors
• Solid-State (CZT) Detectors
• Single-Head Systems
• Multi-Head Systems

By Application

• Cardiology
• Neurology
• Oncology
• Bone & Musculoskeletal Imaging
• Renal, Pulmonary, and Endocrine Studies
• Others

By End-User

• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Mediso Ltd.
• Siemens Healthineers AG
• General Electric Company
• Bruker Corporation
• MiE GmbH
• Digirad Corporation
• Spectrum Dynamics Medical Inc.
• Curium Pharma
• Cardinal Health Inc.
• NTP Radioisotopes SOC Ltd.
• Gamma Medica Inc.
• Lantheus Medical Imaging Inc.
• Bracco Imaging S.p.A.
• Guerbet S.A.
• Neusoft Corporation

Frequently Asked Questions (FAQs)